Vulvar leukoplakia: therapeutic options.

Area of Science:

• Gynecological dermatology
• Vulvar pathology

Background:

• Vulvar leukoplakia is a clinical term, not a histological diagnosis, often representing vulvar lichen sclerosus or squamous cell hyperplasia.
• These conditions share similar causes, symptoms, and treatments but differ histologically, impacting quality of life and carrying malignancy risk.
• Conventional treatments like topical corticosteroids have side effects and limited patient acceptance, necessitating alternative therapies.

Purpose of the Study:

• To review current and emerging therapeutic options for vulvar leukoplakia.
• To highlight the limitations of conventional treatments and the need for safer, more effective alternatives.

Main Methods:

• Review of existing literature on vulvar leukoplakia treatments.
• Discussion of conventional therapies including corticosteroids, calcineurin inhibitors, retinoids, and surgical options.
• Exploration of novel therapeutic approaches such as platelet-rich plasma and laser treatments.

Main Results:

• Topical corticosteroids are first-line but have side effects and variable efficacy.
• Alternative therapies like calcineurin inhibitors and retinoids offer options but may not be universally effective.
• Newer treatments including platelet-rich plasma and laser therapies show promise in improving outcomes while mitigating side effects, though many are in early stages.

Conclusions:

• Vulvar leukoplakia management requires careful consideration of treatment risks and benefits.
• Novel therapeutic strategies are being developed to enhance treatment efficacy and patient tolerance.
• Further research is needed to establish the long-term effectiveness and safety of emerging treatments for vulvar leukoplakia.